We describe here one DLT of recurrent Grade 3 Adenocarcinoma (Neo Adjuvant/ Adjuvant setting) and a DLT of Grade 3 Adenocarcinoma (Neo No Prior Taxane).

**Clinical outcomes**

Response in TNBC patients refractory to paclitaxel in advanced/metastatic setting

- **Table 1**
  - TNBC patients refractory to paclitaxel in advanced/metastatic setting.
  - **P** values represent baseline characteristics of patients previously refractory to paclitaxel in the metastatic setting.

**Background and rationale**

Primary TNBC Tumor Show High-Glucose Expression

**Methods**

**Clinical outcomes**

Response in TNBC patients treated with paclitaxel in the neo-adjuvant setting

- **Table 2**
  - TNBC patients treated with paclitaxel in the neo-adjuvant setting.

**Summary and conclusions**

- CB-839 is well tolerated in combination with paclitaxel in TNBC patients.
- The combination of CB-839 with paclitaxel has encouraging efficacy in TNBC patients.
- The objective response rate (ORR) and 90% disease control rate at 400 mg BID dose level.
- Two of five paclitaxel refractory TNBC patients achieved a PR.
- Additional clinical development with CB-839 + paclitaxel is warranted.
- Study is continuing to enroll patients with and without prior paclitaxel.

**References**